CS259536B2 - Method of insulin's new derivatives production - Google Patents

Method of insulin's new derivatives production Download PDF

Info

Publication number: CS259536B2
Authority: CS; Czechoslovakia
Prior art keywords: formula; amino; iii; threonine; defined above
Prior art date: 1985-03-12

Application number

CS861666A

Other languages

Czech (cs)

English (en)

Other versions

CS166686A2 (en

Inventor

Jan Markussen

Original Assignee

Novo Industri As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-03-12

Filing date

1986-03-11

Publication date

1988-10-14

1986-03-11 Application filed by Novo Industri As filed Critical Novo Industri As

1987-12-17 Publication of CS166686A2 publication Critical patent/CS166686A2/cs

1988-10-14 Publication of CS259536B2 publication Critical patent/CS259536B2/cs

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 214
238000000034 method Methods 0.000 title claims description 63
229940125396 insulin Drugs 0.000 title abstract description 88
102000004877 Insulin Human genes 0.000 title abstract description 82
108090001061 Insulin Proteins 0.000 title abstract description 82
238000004519 manufacturing process Methods 0.000 title description 9
150000001413 amino acids Chemical class 0.000 claims abstract description 37
230000007935 neutral effect Effects 0.000 claims abstract description 14
150000001875 compounds Chemical class 0.000 claims description 94
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 73
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 65
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 63
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 49
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 37
229940024606 amino acid Drugs 0.000 claims description 37
235000001014 amino acid Nutrition 0.000 claims description 35
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 33
239000004473 Threonine Substances 0.000 claims description 31
229960002898 threonine Drugs 0.000 claims description 31
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 27
125000001424 substituent group Chemical group 0.000 claims description 27
239000004472 Lysine Substances 0.000 claims description 17
125000000539 amino acid group Chemical group 0.000 claims description 17
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 15
235000018977 lysine Nutrition 0.000 claims description 15
235000008521 threonine Nutrition 0.000 claims description 15
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims description 14
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 14
235000004554 glutamine Nutrition 0.000 claims description 14
239000004475 Arginine Substances 0.000 claims description 13
229960003121 arginine Drugs 0.000 claims description 13
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 13
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
235000009697 arginine Nutrition 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 12
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 11
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
108090000631 Trypsin Proteins 0.000 claims description 10
102000004142 Trypsin Human genes 0.000 claims description 10
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 10
239000012588 trypsin Substances 0.000 claims description 10
229930064664 L-arginine Natural products 0.000 claims description 9
235000014852 L-arginine Nutrition 0.000 claims description 9
125000003277 amino group Chemical group 0.000 claims description 7
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
235000004279 alanine Nutrition 0.000 claims description 6
229960003767 alanine Drugs 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000006239 protecting group Chemical group 0.000 claims description 6
WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical group CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 6
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 5
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
229960001230 asparagine Drugs 0.000 claims description 5
235000009582 asparagine Nutrition 0.000 claims description 5
108090000765 processed proteins & peptides Proteins 0.000 claims description 5
229960004441 tyrosine Drugs 0.000 claims description 5
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
235000002374 tyrosine Nutrition 0.000 claims description 5
229960004295 valine Drugs 0.000 claims description 5
239000004474 valine Substances 0.000 claims description 5
102000004190 Enzymes Human genes 0.000 claims description 4
108090000790 Enzymes Proteins 0.000 claims description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
229930182817 methionine Natural products 0.000 claims description 4
235000006109 methionine Nutrition 0.000 claims description 4
239000002773 nucleotide Substances 0.000 claims description 4
125000003729 nucleotide group Chemical group 0.000 claims description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
229960005190 phenylalanine Drugs 0.000 claims description 4
235000008729 phenylalanine Nutrition 0.000 claims description 4
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
102000007079 Peptide Fragments Human genes 0.000 claims description 3
108010033276 Peptide Fragments Proteins 0.000 claims description 3
241001104043 Syringa Species 0.000 claims description 3
235000004338 Syringa vulgaris Nutrition 0.000 claims description 3
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid ester group Chemical group C(CCCCCCCCCCC)(=O)O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
229960000310 isoleucine Drugs 0.000 claims description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
230000001810 trypsinlike Effects 0.000 claims description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
241000590035 Achromobacter lyticus Species 0.000 claims description 2
108010065920 Insulin Lispro Proteins 0.000 claims description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
108091005804 Peptidases Proteins 0.000 claims description 2
239000004365 Protease Substances 0.000 claims description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
125000003545 alkoxy group Chemical group 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
239000012634 fragment Substances 0.000 claims description 2
229960002743 glutamine Drugs 0.000 claims description 2
229960003136 leucine Drugs 0.000 claims description 2
235000004400 serine Nutrition 0.000 claims description 2
229960001153 serine Drugs 0.000 claims description 2
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims 5
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 4
OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 2
PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 claims 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
235000013922 glutamic acid Nutrition 0.000 claims 2
239000004220 glutamic acid Substances 0.000 claims 2
229960002449 glycine Drugs 0.000 claims 2
229960004452 methionine Drugs 0.000 claims 2
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
101000642823 Solanum tuberosum Granule-bound starch synthase 2, chloroplastic/amyloplastic Proteins 0.000 claims 1
QBMYYTXUDRARHD-SFYZADRCSA-N arginine ornithine Chemical compound NCCC[C@@H](N)C(=O)OC(=O)[C@@H](N)CCCN=C(N)N QBMYYTXUDRARHD-SFYZADRCSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 1
229910052739 hydrogen Inorganic materials 0.000 claims 1
239000001257 hydrogen Substances 0.000 claims 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract description 45
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract description 43
230000002035 prolonged effect Effects 0.000 abstract description 13
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 9
125000004185 ester group Chemical group 0.000 abstract description 5
125000003368 amide group Chemical group 0.000 abstract description 4
210000004899 c-terminal region Anatomy 0.000 abstract description 4
239000000243 solution Substances 0.000 description 52
235000013350 formula milk Nutrition 0.000 description 46
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 36
239000000203 mixture Substances 0.000 description 34
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
239000000047 product Substances 0.000 description 19
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 15
239000011701 zinc Substances 0.000 description 15
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 14
108090000623 proteins and genes Proteins 0.000 description 14
VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 13
239000002243 precursor Substances 0.000 description 13
229910052725 zinc Inorganic materials 0.000 description 13
108010005991 Pork Regular Insulin Proteins 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
238000005119 centrifugation Methods 0.000 description 12
238000001962 electrophoresis Methods 0.000 description 12
235000018102 proteins Nutrition 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 12
239000013078 crystal Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 10
239000000463 material Substances 0.000 description 10
239000002244 precipitate Substances 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000004128 high performance liquid chromatography Methods 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
239000000872 buffer Substances 0.000 description 8
-1 methiomine Chemical compound 0.000 description 8
239000002253 acid Substances 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000001103 potassium chloride Substances 0.000 description 7
235000011164 potassium chloride Nutrition 0.000 description 7
239000002904 solvent Substances 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
239000003755 preservative agent Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
150000001408 amides Chemical class 0.000 description 5
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 5
239000001639 calcium acetate Substances 0.000 description 5
235000011092 calcium acetate Nutrition 0.000 description 5
229960005147 calcium acetate Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000002335 preservative effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
229920005654 Sephadex Polymers 0.000 description 4
239000012507 Sephadex™ Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
239000008103 glucose Substances 0.000 description 4
239000004026 insulin derivative Substances 0.000 description 4
229940119528 pork insulin Drugs 0.000 description 4
238000003756 stirring Methods 0.000 description 4
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
239000012736 aqueous medium Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
239000004246 zinc acetate Substances 0.000 description 3
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
108010075254 C-Peptide Proteins 0.000 description 2
YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
235000019766 L-Lysine Nutrition 0.000 description 2
ULEBESPCVWBNIF-BYPYZUCNSA-N L-arginine amide Chemical compound NC(=O)[C@@H](N)CCCNC(N)=N ULEBESPCVWBNIF-BYPYZUCNSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
108010076181 Proinsulin Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
101000993800 Sus scrofa Insulin Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
229960002303 citric acid monohydrate Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
IYWCBYFJFZCCGV-UHFFFAOYSA-N formamide;hydrate Chemical compound O.NC=O IYWCBYFJFZCCGV-UHFFFAOYSA-N 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000005457 ice water Substances 0.000 description 2
150000003951 lactams Chemical group 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000013589 supplement Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 2
239000011592 zinc chloride Substances 0.000 description 2
235000005074 zinc chloride Nutrition 0.000 description 2
239000011746 zinc citrate Substances 0.000 description 2
235000006076 zinc citrate Nutrition 0.000 description 2
229940068475 zinc citrate Drugs 0.000 description 2
PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 description 1
FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
108010065691 Biphasic Insulins Proteins 0.000 description 1
101001011741 Bos taurus Insulin Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
COVXELOAORHTND-LSJOCFKGSA-N Gly-Ile-Val Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O COVXELOAORHTND-LSJOCFKGSA-N 0.000 description 1
101001114057 Homo sapiens P antigen family member 1 Proteins 0.000 description 1
102000005237 Isophane Insulin Human genes 0.000 description 1
108010081368 Isophane Insulin Proteins 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
150000008575 L-amino acids Chemical group 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
108010053229 Lysyl endopeptidase Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
102100023219 P antigen family member 1 Human genes 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000005189 alkyl hydroxy group Chemical group 0.000 description 1
235000020616 amino acid formula Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
108010068380 arginylarginine Proteins 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
239000000189 biphasic insulin Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
230000002301 combined effect Effects 0.000 description 1
238000011188 deamidation reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000000539 dimer Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000007974 sodium acetate buffer Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000011135 tin Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Diabetes (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CS861666A 1985-03-12 1986-03-11 Method of insulin's new derivatives production CS259536B2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK113585A DK113585D0 (da)	1985-03-12	1985-03-12	Nye peptider

Publications (2)

Publication Number	Publication Date
CS166686A2 CS166686A2 (en)	1987-12-17
CS259536B2 true CS259536B2 (en)	1988-10-14

Family

ID=8101410

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS861666A CS259536B2 (en)	1985-03-12	1986-03-11	Method of insulin's new derivatives production

Country Status (22)

Country	Link
EP (1)	EP0194864B1 (de)
JP (1)	JPS61212598A (de)
KR (1)	KR930007433B1 (de)
CN (1)	CN86101489A (de)
AT (1)	ATE77391T1 (de)
AU (1)	AU612964B2 (de)
CS (1)	CS259536B2 (de)
DD (1)	DD244345A5 (de)
DE (1)	DE3685668T2 (de)
DK (2)	DK113585D0 (de)
ES (1)	ES8800276A1 (de)
FI (1)	FI861007L (de)
GR (1)	GR860687B (de)
HU (1)	HU201097B (de)
IL (1)	IL78103A0 (de)
MY (1)	MY102102A (de)
NO (1)	NO172441C (de)
NZ (1)	NZ215445A (de)
PH (1)	PH24260A (de)
PT (1)	PT82173B (de)
YU (1)	YU46001B (de)
ZA (1)	ZA861432B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK347086D0 (da) *	1986-07-21	1986-07-21	Novo Industri As	Novel peptides
US5008241A (en) *	1985-03-12	1991-04-16	Novo Nordisk A/S	Novel insulin peptides
DK119785D0 (da) *	1985-03-15	1985-03-15	Nordisk Gentofte	Insulinpraeparat
DK437786D0 (da) *	1986-09-12	1986-09-12	Nordisk Gentofte	Insulinprecursorer
ATE93238T1 (de) *	1988-07-20	1993-09-15	Novo Nordisk As	Menschliche insulinanalage und zubereitungen daraus.
DE3827533A1 (de) *	1988-08-13	1990-02-15	Hoechst Ag	Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) *	1988-11-08	1990-05-10	Hoechst Ag	Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DK134189D0 (da) *	1989-03-20	1989-03-20	Nordisk Gentofte	Insulinforbindelser
US5130298A (en) *	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
DE3936876A1 (de) *	1989-11-06	1991-05-23	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US6933272B1 (en)	1998-09-22	2005-08-23	Erik Helmerhorst	Use of non-peptidyl compounds for the treatment of insulin related ailments
AUPP609198A0 (en) *	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
DE10114178A1 (de)	2001-03-23	2002-10-10	Aventis Pharma Gmbh	Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de)	2002-06-18	2004-01-15	Aventis Pharma Deutschland Gmbh	Saure Insulinzubereitungen mit verbesserter Stabilität
EP2368579A1 (de)	2004-01-21	2011-09-28	Novo Nordisk Health Care AG	Tranglutaminase vermittelte konjugation von peptiden.
US20090074882A1 (en)	2005-12-28	2009-03-19	Novo Nordisk A/S	Insulin compositions and method of making a composition
DE102006031962A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Amidiertes Insulin Glargin
DE102006031955A1 (de) *	2006-07-11	2008-01-17	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
NZ586589A (en) *	2008-01-09	2012-04-27	Sanofi Aventis Deutschland	Novel insulin analogues having an extremely delayed time-action profile
PL2229407T3 (pl)	2008-01-09	2017-06-30	Sanofi-Aventis Deutschland Gmbh	Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
DE102008003566A1 (de) *	2008-01-09	2009-07-16	Sanofi-Aventis Deutschland Gmbh	Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP3228320B1 (de)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
EP3202394A1 (de)	2009-07-06	2017-08-09	Sanofi-Aventis Deutschland GmbH	Wässrige insulinzubereitungen enthaltend methionin
US20120241356A1 (en) *	2009-07-06	2012-09-27	Sanofi-Aventis Deutschland Gmbh	Heat- and vibration-stable insulin preparations
PE20121316A1 (es)	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
PT2554183T (pt)	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
EP2569002B1 (de) *	2010-05-10	2016-10-26	Novo Nordisk A/S	Verfahren zur herstellung von insulin-zink komlexen
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN102174495A (zh) *	2011-01-20	2011-09-07	马忠仁	一种提取糜胰蛋白酶的方法
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10335464B1 (en)	2018-06-26	2019-07-02	Novo Nordisk A/S	Device for titrating basal insulin
CN114096269B (zh)	2019-07-12	2024-06-11	诺和诺德股份有限公司	高浓度胰岛素制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK319780A (da) *	1980-07-24	1982-01-25	Forenede Bryggerier As	Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
DE3326472A1 (de) *	1983-07-22	1985-02-14	Hoechst Ag, 6230 Frankfurt	Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) *	1983-09-17	1985-04-25	Hoechst Ag, 6230 Frankfurt	Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DK119785D0 (da) *	1985-03-15	1985-03-15	Nordisk Gentofte	Insulinpraeparat

1985
- 1985-03-12 DK DK113585A patent/DK113585D0/da unknown
1986
- 1986-02-26 ZA ZA861432A patent/ZA861432B/xx unknown
- 1986-02-27 PH PH33459A patent/PH24260A/en unknown
- 1986-03-10 DD DD86287734A patent/DD244345A5/de not_active IP Right Cessation
- 1986-03-10 YU YU34586A patent/YU46001B/sh unknown
- 1986-03-10 DK DK107086A patent/DK158677C/da active
- 1986-03-11 JP JP61051586A patent/JPS61212598A/ja active Pending
- 1986-03-11 EP EP86301755A patent/EP0194864B1/de not_active Expired - Lifetime
- 1986-03-11 ES ES552879A patent/ES8800276A1/es not_active Expired
- 1986-03-11 CS CS861666A patent/CS259536B2/cs unknown
- 1986-03-11 PT PT82173A patent/PT82173B/pt not_active IP Right Cessation
- 1986-03-11 NZ NZ215445A patent/NZ215445A/xx unknown
- 1986-03-11 AU AU54495/86A patent/AU612964B2/en not_active Ceased
- 1986-03-11 KR KR1019860001737A patent/KR930007433B1/ko not_active Expired - Lifetime
- 1986-03-11 HU HU861024A patent/HU201097B/hu not_active IP Right Cessation
- 1986-03-11 FI FI861007A patent/FI861007L/fi not_active Application Discontinuation
- 1986-03-11 CN CN198686101489A patent/CN86101489A/zh active Pending
- 1986-03-11 DE DE8686301755T patent/DE3685668T2/de not_active Expired - Fee Related
- 1986-03-11 AT AT86301755T patent/ATE77391T1/de not_active IP Right Cessation
- 1986-03-11 IL IL78103A patent/IL78103A0/xx not_active IP Right Cessation
- 1986-03-11 NO NO860920A patent/NO172441C/no unknown
- 1986-03-12 GR GR860687A patent/GR860687B/el unknown
1987
- 1987-09-30 MY MYPI87002520A patent/MY102102A/en unknown

Also Published As

Publication number	Publication date
AU612964B2 (en)	1991-07-25
ES8800276A1 (es)	1987-11-01
CN86101489A (zh)	1987-01-21
DK107086A (da)	1986-11-07
YU34586A (en)	1988-10-31
AU5449586A (en)	1986-09-18
NO172441C (no)	1993-07-21
DE3685668D1 (en)	1992-07-23
NO860920L (no)	1986-09-15
DE3685668T2 (de)	1993-01-14
YU46001B (sh)	1992-12-21
EP0194864A2 (de)	1986-09-17
KR860007288A (ko)	1986-10-10
PH24260A (en)	1990-05-04
MY102102A (en)	1992-03-31
KR930007433B1 (ko)	1993-08-10
DK113585D0 (da)	1985-03-12
HU201097B (en)	1990-09-28
HUT41052A (en)	1987-03-30
DD244345A5 (de)	1987-04-01
DK158677B (da)	1990-07-02
GR860687B (en)	1986-07-11
NZ215445A (en)	1989-07-27
EP0194864A3 (en)	1989-01-11
NO172441B (no)	1993-04-13
PT82173B (pt)	1988-07-29
JPS61212598A (ja)	1986-09-20
PT82173A (en)	1986-04-01
FI861007A0 (fi)	1986-03-11
DK158677C (da)	1990-12-31
ZA861432B (en)	1986-11-26
FI861007A7 (fi)	1986-09-13
EP0194864B1 (de)	1992-06-17
FI861007L (fi)	1986-09-13
CS166686A2 (en)	1987-12-17
IL78103A0 (en)	1986-07-31
ATE77391T1 (de)	1992-07-15
ES552879A0 (es)	1987-11-01
DK107086D0 (da)	1986-03-10

Publication	Publication Date	Title
CS259536B2 (en)	1988-10-14	Method of insulin's new derivatives production
EP0254516B1 (de)	1994-01-05	Peptide
US4701440A (en)	1987-10-20	Insulin derivatives, processes for their preparation and their use, and pharmaceutical agents for the treatment of diabetes mellitus
FI79786C (fi)	1990-03-12	Foerfarande foer framstaellning ett farmaceutiskt medel foer behandling av diabetes.
US5008241A (en)	1991-04-16	Novel insulin peptides
EP0235205B1 (de)	1992-10-28	Peptidanalogedes insulinähnlichen wachstumsfaktors-1 bei säugetieren
US4946828A (en)	1990-08-07	Novel insulin peptides
US6451970B1 (en)	2002-09-17	Peptide derivatives
US5631347A (en)	1997-05-20	Reducing gelation of a fatty acid-acylated protein
AU612141B2 (en)	1991-07-04	Novel insulin derivatives
EP0536245A1 (de)	1993-04-14	Neuartige insulinanaloge mit verlängerte wirkdauer
JPH0691834B2 (ja)	1994-11-16	インシュリン誘導体の製法
US4569792A (en)	1986-02-11	Anti-diabetic compounds
CA1243972A (en)	1988-11-01	Anti-diabetic compounds
KR920005659B1 (ko)	1992-07-13	인슐린 유도체의 제조방법
MXPA97003508A (en)	1997-12-01	Insulin analogs axila
DK160880B (da)	1991-04-29	Insulinderivater samt injicerbare oploesninger indeholdende disse
HK1014010A (en)	1999-09-17	Reducing gelation of a fatty acid acylated protein using a citrate buffer